Skip to main
COLL

Collegium Pharmaceutical (COLL) Stock Forecast & Price Target

Collegium Pharmaceutical (COLL) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 60%
Buy 20%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Collegium Pharmaceutical Inc. is experiencing a positive trajectory in its financial performance, highlighted by a significant 19% year-over-year revenue growth for Jornay PM, which reached $42 million, surpassing market expectations. The product has gained a noteworthy market share of 23.4%, up from approximately 17% in the previous quarter, with a robust script growth driven by increased prescriptions among both pediatric and adult patients. With the ongoing enhancements in gross-to-net (GTN) improvements and the expansion of its sales force, Collegium is poised for sustained growth, particularly with Jornay PM serving as a key driver in the coming years.

Bears say

Collegium Pharmaceutical Inc. is facing a negative outlook due to projected declines in sales for critical products, including Xtampza ER and Belbuca, which are anticipated to contribute approximately $620 million in revenue by 2026, representing a year-over-year decrease. The company also faces significant risks from potential generic competition affecting its pain portfolio, coupled with higher-than-expected expenditures that could hinder profitability. Additionally, uncertain commercialization prospects, including potential delays, quality issues from third-party suppliers, and unfavorable pricing dynamics, further exacerbate the challenges to achieving its financial targets.

Collegium Pharmaceutical (COLL) has been analyzed by 5 analysts, with a consensus rating of Buy. 60% of analysts recommend a Strong Buy, 20% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Collegium Pharmaceutical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Collegium Pharmaceutical (COLL) Forecast

Analysts have given Collegium Pharmaceutical (COLL) a Buy based on their latest research and market trends.

According to 5 analysts, Collegium Pharmaceutical (COLL) has a Buy consensus rating as of Apr 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $51.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $51.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Collegium Pharmaceutical (COLL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.